antiviral and associated therapy - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death or transfer to ICU 1.09 [0.99, 1.20]< 10%1 study (1/-)4.0 %some concernnot evaluable moderatecrucial-
deaths 1.02 [0.96, 1.09]< 10%26 studies (26/-)24.1 %some concerncritical moderatecrucial-
deaths (time to event analysis only) 1.01 [0.92, 1.12]< 140%5 studies (5/-)41.1 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.98 [0.72, 1.32]< 10%7 studies (7/-)56.4 %some concernnot evaluable moderateimportant-
clinical improvement 1.32 [1.19, 1.47]> 10%11 studies (11/-)100.0 %some concernlow moderateimportant-
clinical improvement (14-day) 1.35 [1.16, 1.58]> 10%9 studies (9/-)100.0 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.42 [1.13, 1.79]> 138%6 studies (6/-)99.9 %some concernserious moderateimportant-
clinical improvement (7-day) 1.34 [1.07, 1.67]> 10%6 studies (6/-)99.5 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.43 [1.19, 1.71]> 10%4 studies (4/-)100.0 %some concernnot evaluable moderateimportant-
death or ventilation 1.03 [0.95, 1.13]< 138%5 studies (5/-)22.0 %some concernnot evaluable moderateimportant-
hospital discharge 1.02 [0.94, 1.11]> 152%3 studies (3/-)69.4 %some concernnot evaluable moderateimportant-
PCR-negative conversion 1.43 [0.99, 2.05]> 163%10 studies (10/-)97.2 %some concernlow moderateimportant-
PCR-negative conversion (14-day) 0.99 [0.93, 1.06]> 10%7 studies (7/-)40.5 %some concernnot evaluable moderateimportant-
PCR-negative conversion (7-day) 1.03 [0.83, 1.29]> 144%6 studies (6/-)61.3 %some concernnot evaluable moderateimportant-
PCR-negative conversion (time to event analysis only) 1.32 [1.03, 1.69]> 10%2 studies (2/-)98.6 %some concernnot evaluable moderateimportant-
radiologic improvement (14-day) 0.29 [0.03, 2.67]> 10%2 studies (2/-)14.0 %some concernnot evaluable moderateimportant-
radiologic improvement (7-day) 0.09 [0.01, 0.78]> 10%2 studies (2/-)1.5 %some concernnot evaluable moderateimportant-
ventilation 0.60 [0.17, 2.18]< 141%4 studies (4/-)78.1 %some concernnot evaluable moderateimportant-
ventilation (time to event analysis only) 0.06 [0.01, 0.83]< 10%1 study (1/-)98.2 %some concernnot evaluable moderateimportant-
ICU admission 0.99 [0.52, 1.90]< 10%4 studies (4/-)50.8 %some concernnot evaluable moderatenon important-

safety endpoints 00

AE leading to drug discontinuation 2.43 [0.79, 7.45]< 10%1 study (1/-)6.0 %lownot evaluable highimportant-
cardiac arrest 1.92 [0.35, 10.49]< 10%1 study (1/-)22.7 %some concernnot evaluable moderateimportant-
serious adverse events 0.70 [0.55, 0.88]< 10%7 studies (7/-)99.9 %some concernnot evaluable moderateimportant-
adverse events 1.53 [1.17, 2.00]< 127%10 studies (10/-)0.1 %some concernlow moderatenon important-
arrhythmia 1.01 [0.77, 1.33]< 10%2 studies (2/-)47.5 %some concernnot evaluable moderatenon important-
deep vein thrombosis 0.62 [0.23, 1.64]< 10%2 studies (2/-)83.1 %some concernnot evaluable moderatenon important-
elevated liver enzymes 0.58 [0.34, 0.97]< 16%2 studies (2/-)98.1 %some concernnot evaluable moderatenon important-
hyperbilirubinemia 0.97 [0.48, 1.93]< 10%2 studies (2/-)53.8 %some concernnot evaluable moderatenon important-
long QT 9.79 [1.27, 75.50]< 10%1 study (1/-)1.5 %some concernnot evaluable moderatenon important-
pulmonary embolism 0.82 [0.20, 3.29]< 10%2 studies (2/-)61.1 %some concernnot evaluable moderatenon important-
renal impairment 1.02 [0.64, 1.61]< 10%2 studies (2/-)47.2 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.